-+ 0.00%
-+ 0.00%
-+ 0.00%

Biocytogen licenses fully human VHH antibody to Qilu Pharma in non-exclusive deal

PUBT·09/02/2026 12:00:35
Listen to the news
Biocytogen licenses fully human VHH antibody to Qilu Pharma in non-exclusive deal
  • Biocytogen signed a non-exclusive licensing deal with Qilu Pharma for a fully human VHH antibody targeting neuroscience R&D.
  • Qilu received non-exclusive rights to the VHH molecule generated from Biocytogen’s RenNano platform.
  • Biocytogen will receive an upfront payment, with eligibility for development, regulatory, and commercial milestone payments.
  • Financial terms were not disclosed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biocytogen Pharmaceuticals Beijing Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609020800BIZWIRE_USPR_____20260902_BW284511) on September 02, 2026, and is solely responsible for the information contained therein.